Ausgabe 6/2021
Inhalt (25 Artikel)
Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs)
Violetta Dymicka-Piekarska, Olga M. Koper-Lenkiewicz, Justyna Zińczuk, Ewa Kratz, Joanna Kamińska
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
Fausto Meriggi, Alberto Zaniboni
Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma
O. Jimenez, S. Colli, M. Garcia Lombardi, M. V. Preciado, E. De Matteo, P. Chabay
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review
Zhe Zhao, Xinfeng Wang, Xiu-qi Bao, Jingwen Ning, Meiyu Shang, Dan Zhang
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy
Gilli Galore-Haskel, Eyal Greenberg, Inbal Yahav, Ettai Markovits, Rona Ortenberg, Ronnie Shapira-Fromer, Orit Itzhaki, Jacob Schachter, Michal J. Besser, Gal Markel
Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma
Nuchjira Takheaw, Gunya Sittithumcharee, Ryusho Kariya, Watchara Kasinrerk, Seiji Okada
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo
G. de Jong, L. Bartels, M. Kedde, E. M. E. Verdegaal, M. A. Gillissen, S. E. Levie, M. G. Cercel, S. E. van Hal-van Veen, C. Fatmawati, D. van de Berg, E. Yasuda, Y. B. Claassen, A. Q. Bakker, S. H. van der Burg, R. Schotte, J. Villaudy, H. Spits, M. D. Hazenberg, P. M. van Helden, K. Wagner
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Vincenzo Di Noia, Ettore D’Argento, Sara Pilotto, Emanuele Vita, Miriam Grazia Ferrara, Paola Damiano, Marta Ribelli, Antonella Cannella, Antonella Virtuoso, Andrea Fattorossi, Giovanni Luca Ceresoli, Michele Milella, Giordano Domenico Beretta, Giampaolo Tortora, Emilio Bria
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab
Nalee Kim, Jeong Il Yu, Hee Chul Park, Gyu Sang Yoo, Changhoon Choi, Jung Yong Hong, Ho Yeong Lim, Jeeyun Lee, Moon Seok Choi, Jung Eun Lee, Kyunga Kim
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
Changhee Park, Kyeonghun Jeong, Joon-Hyeong Park, Sohee Jung, Jeong Mo Bae, Kwangsoo Kim, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Ju-Seog Lee, Dong-Wan Kim, Gyeong Hoon Kang, Doo Hyun Chung, Dae Seog Heo
Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10
Boxing Su, Haibo Han, Yanqing Gong, Xuesong Li, Chaoyue Ji, Jingjing Yao, Jianghui Yang, Weiguo Hu, Wei Zhao, Jianxing Li, Gang Zhang, Liqun Zhou
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Lukas Peiffer, Farnoush Farahpour, Ashwin Sriram, Ivelina Spassova, Daniel Hoffmann, Linda Kubat, Patrizia Stoitzner, Thilo Gambichler, Antje Sucker, Selma Ugurel, Dirk Schadendorf, Jürgen C. Becker
Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer
He Zhang, Guohui Qin, Hui Yu, Xu Han, Sha Zhu
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Marzia Del Re, Federico Cucchiara, Eleonora Rofi, Lorenzo Fontanelli, Iacopo Petrini, Nicole Gri, Giulia Pasquini, Mimma Rizzo, Michela Gabelloni, Lorenzo Belluomini, Stefania Crucitta, Raffaele Ciampi, Antonio Frassoldati, Emanuele Neri, Camillo Porta, Romano Danesi
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations
Barbara Willvonseder, Fabian Stögbauer, Katja Steiger, Moritz Jesinghaus, Peer-Hendrik Kuhn, Christine Brambs, Jutta Engel, Holger Bronger, Georg Philipp Schmidt, Bernhard Haller, Wilko Weichert, Gisela Keller, Aurelia Noske, Nicole Pfarr, Melanie Boxberg
Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
Carlos Zamora, Mariona Riudavets, Georgia Anguera, Letícia Alserawan, Ivana Sullivan, Andrés Barba, Jorgina Serra, M. Angels Ortiz, Pablo Gallardo, Lidia Perea, Javier Gavira, Agustí Barnadas, Margarita Majem, Silvia Vidal
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
Ming Yi, Anping Li, Linghui Zhou, Qian Chu, Suxia Luo, Kongming Wu
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers
Qingzhu Liu, Lei Jiang, Ke Li, Hang Li, Gaochao Lv, Jianguo Lin, Ling Qiu
Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
Gisela María Suárez, Ana Laura Añé-Kourí, Amnely González, Patricia Lorenzo-Luaces, Elia Neninger, Eva Elena Salomón, Leamnet Cordero, Mauricio Catalá, Nuris Ledón, Karla Pereira, Malkon Guillermo Sánchez, Beatriz García, Tania Crombet, Zaima Mazorra, Danay Saavedra, Agustin Lage
Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Shinkichi Takamori, Kazuki Takada, Mototsugu Shimokawa, Mikako Jinnnouchi, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Tetsuzo Tagawa, Masaki Mori
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
Shin Hye Yoo, Jihui Yun, Bhumsuk Keam, Seung-Pyo Hong, Chan-Young Ock, Jaemoon Koh, Sehui Kim, Yoon Kyung Jeon, Kyeong Cheon Jung, Miso Kim, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim, Dae Seog Heo
The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro
Mario Presti, Marie Christine Wulff Westergaard, Arianna Draghi, Christopher Aled Chamberlain, Aishwarya Gokuldass, Inge Marie Svane, Marco Donia
Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years
Fausto Petrelli, Alessandro Inno, Antonio Ghidini, Stefania Gori, Melissa Bersanelli
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
Simon Fietz, Romina Zarbl, Dennis Niebel, Christian Posch, Peter Brossart, Gerrit H. Gielen, Sebastian Strieth, Torsten Pietsch, Glen Kristiansen, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy
Qingsheng Li, Phuong T. Ngo, Nejat K. Egilmez